CN114081867B - 一种提高微球载药量的方法 - Google Patents
一种提高微球载药量的方法 Download PDFInfo
- Publication number
- CN114081867B CN114081867B CN202111311957.4A CN202111311957A CN114081867B CN 114081867 B CN114081867 B CN 114081867B CN 202111311957 A CN202111311957 A CN 202111311957A CN 114081867 B CN114081867 B CN 114081867B
- Authority
- CN
- China
- Prior art keywords
- microspheres
- emulsion
- polyvinyl alcohol
- acdx
- grinding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 195
- 239000003814 drug Substances 0.000 title claims abstract description 159
- 229940079593 drug Drugs 0.000 title claims abstract description 147
- 238000011068 loading method Methods 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 31
- 239000000839 emulsion Substances 0.000 claims abstract description 113
- 239000002245 particle Substances 0.000 claims abstract description 104
- 239000003960 organic solvent Substances 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000000084 colloidal system Substances 0.000 claims abstract description 12
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 109
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 109
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 87
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 84
- 229920002307 Dextran Polymers 0.000 claims description 46
- 229940063675 spermine Drugs 0.000 claims description 42
- 238000000227 grinding Methods 0.000 claims description 33
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 32
- 239000012498 ultrapure water Substances 0.000 claims description 32
- 238000001035 drying Methods 0.000 claims description 31
- 238000005406 washing Methods 0.000 claims description 31
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 22
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 22
- 239000011324 bead Substances 0.000 claims description 12
- 229960004584 methylprednisolone Drugs 0.000 claims description 12
- 229960003530 donepezil Drugs 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 10
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 8
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 8
- 229960005370 atorvastatin Drugs 0.000 claims description 8
- 229960004083 methazolamide Drugs 0.000 claims description 8
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 claims description 8
- 229960000485 methotrexate Drugs 0.000 claims description 8
- 229960002537 betamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 238000005538 encapsulation Methods 0.000 abstract description 38
- 238000004945 emulsification Methods 0.000 abstract description 20
- 238000009826 distribution Methods 0.000 abstract description 16
- 229920000642 polymer Polymers 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 5
- 239000003995 emulsifying agent Substances 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 101
- 239000012071 phase Substances 0.000 description 85
- 239000003921 oil Substances 0.000 description 51
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 46
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- 239000007864 aqueous solution Substances 0.000 description 32
- 239000008346 aqueous phase Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 25
- 102000004877 Insulin Human genes 0.000 description 23
- 108090001061 Insulin Proteins 0.000 description 23
- 229940125396 insulin Drugs 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000000523 sample Substances 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 238000009210 therapy by ultrasound Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- -1 duloxetide Chemical compound 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 10
- 108010011459 Exenatide Proteins 0.000 description 10
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 10
- 238000001723 curing Methods 0.000 description 10
- 229960001519 exenatide Drugs 0.000 description 10
- 238000009792 diffusion process Methods 0.000 description 9
- 108050008461 Beta-lactoglobulin Proteins 0.000 description 8
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 8
- 229960004824 triptorelin Drugs 0.000 description 8
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 8
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 7
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 7
- 108010000817 Leuprolide Proteins 0.000 description 7
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 7
- 108010019598 Liraglutide Proteins 0.000 description 7
- 108010016076 Octreotide Proteins 0.000 description 7
- 239000012876 carrier material Substances 0.000 description 7
- 108010021336 lanreotide Proteins 0.000 description 7
- 229960002437 lanreotide Drugs 0.000 description 7
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 7
- 229960004338 leuprorelin Drugs 0.000 description 7
- 229960002701 liraglutide Drugs 0.000 description 7
- 229960002700 octreotide Drugs 0.000 description 7
- 238000000879 optical micrograph Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010021717 Nafarelin Proteins 0.000 description 6
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 6
- 108010055460 bivalirudin Proteins 0.000 description 6
- 229960001500 bivalirudin Drugs 0.000 description 6
- 229920001400 block copolymer Polymers 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229960002866 duloxetine Drugs 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 6
- 229960002333 nafarelin Drugs 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- 239000004626 polylactic acid Substances 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000007590 electrostatic spraying Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000007712 rapid solidification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 229940083957 1,2-butanediol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 1
- MKAFOJAJJMUXLW-UHFFFAOYSA-N N-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CNC)C1=CC=C(OC)C=C1 MKAFOJAJJMUXLW-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960002629 agomelatine Drugs 0.000 description 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 1
- 229950006334 apramycin Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 239000003876 biosurfactant Substances 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 description 1
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N huperzine a Chemical compound N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004310 piribedil Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960004986 pyritinol Drugs 0.000 description 1
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229960005344 tiapride Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及医药领域,公开了一种提高微球载药量的方法,包括:(1)制备含亲油性聚合物的药物胶体微粒;(2)乳化:将含药物胶体微粒的有机溶剂(油相)和含乳化剂的水(水相)混合形成O/W乳剂;(3)快速固化:快速移除乳滴中的有机溶剂,形成微球;由于药物胶体微粒经过聚合物的亲油性伪装后不参与油水两相的分配过程,因此极大地减少了在包载过程中药物的泄露。本发明方法能够使难溶于油相的药物(完全以微粒形式分散于油相)微球包封率达90%以上、能溶于油相的药物(部分以微粒形式分散于油相)微球包封率达80%以上,最终实现微球的高载药。
Description
技术领域
本发明涉及药物制剂技术领域,尤其涉及一种提高微球载药量的方法。
背景技术
微球制剂可以控制药物释放速率,在较长时间范围内维持有效的血药浓度,从而显著降低给药频次,提高患者的用药顺应性。目前已有近20种为微球制剂用于临床治疗,并且多以乳化法进行制备。乳化法制备微球的过程主要包括乳滴的生成及固化两个步骤,乳滴的生成步骤决定了微球对药物的包载效率。由于分子结构不同,药物表现出理化性质(溶解度、分配系数、解离度等)的多样性,以及对油水两相亲和力的差异性。例如,脂溶性药物具有较高的油相亲和力,而水溶性药物对水相的亲和力更高。这种性质差异,极大程度的限制了O/W型乳化法的药物应用范围,并造成了微球对部分药物包载效率低下的现状。相较于药物分子理化性质的多样性,药物微粒表面性质(如荷电性、亲疏水性等)的种类较为有限。在质量相当的情况下,药物微粒,与单个药物分子的改性相比,仅需对微粒表面的分子进行修饰,即可改变整个药物微粒的亲疏水性。
因此,通过制备药物微粒体系,利用药物微粒与载体材料间的相互作用,对微粒表面进行修饰,可以改变药物微粒的亲油性,干预药物微粒在油水两相间的分配,从而实现微球对于不同类型药物的高效包载。此外,对于在油相中有一定溶解度的药物来讲,药物分子的跨界面扩散会导致乳滴内药物微粒的溶解,使药物分子的含量增加,药物参与油水两相间分配的比例上升。而药物分子的跨界面扩散通常具有较为稳定的扩散速率;即单位时间和单位界面面积下,药物分子的扩散量(绝对值)相对稳定。通过增大油相中药物的含量和缩短乳滴固化时间,可有效提高微球对药物分子的包封率和载药量。由于在有限的乳滴固化时间内,分子的扩散总量(绝对值)一定,当体系中投入的药物微粒越多,在有限时间内跨界面扩散的药物量占投入总药物量的比例越低,微球的包封率和载药量越高。
在相同的给药剂量下,微球载药量的提高能够大幅降低辅料用量,减轻辅料及其降解产物所带来的副作用。因此,开发可高效包载不同类型药物的通用性高载药微球制备策略,对拓展O/W型乳化法的药物应用范围、促进微球制剂的临床应用具有重要意义。
发明内容
本发明提供了一种提高微球载药量的方法。本发明方法是一种可高效包载不同类型药物的通用性高载药微球制备策略,能够有效提高在油相中有一定溶解度的药物微球的包封率,可将微球的包封率控制在80%以上,从而显著提高微球的载药量。该发明包括:不参与油水界面分配的药物胶体微粒制备工艺以及乳化后快速固化工艺。
本发明的具体技术方案为:一种提高微球载药量的方法,包括以下步骤:
(1)制备含亲油性聚合物的药物胶体微粒:
将活性药物成分分散于含亲油性聚合物的溶剂I中,形成药物胶体微粒;其中所述的聚合物与药物胶体颗粒电性相反;
(2)乳化:
将含药物胶体微粒的溶剂I(油相)和含乳化剂的溶液I(水相)混合形成O/W乳剂;
(3)快速固化:
乳滴生成后,快速移除乳滴中的有机溶剂,形成微球;
其中,所述含亲油性聚合物的药物胶体微粒的分散方法包括但不限于自发溶剂扩散法、纳米沉积法、超临界流体技术、机械球磨法中的任意一种或几种联用。
其中,所述形成O/W乳剂的乳化方法包括但不限于机械搅拌、高压均质、膜乳化、连续流中的任意一种或几种联用。
其中,所述快速移除乳滴中的有机溶剂的固化方法包括但不限于连续流、旋转蒸发、静电喷雾中的任意一种或几种联用。这里所述快速移除乳滴中的有机溶剂的固化方法是指较常规微球制备的固化时间短,常规微球制备一般需要4~12小时左右,本发明所述的快速移除乳滴中的有机溶剂的固化方法如连续流、旋转蒸发、或静电喷雾等方式,可以实现在半小时内完成微球的固化过程。其中,所述活性药物成分根据在溶剂I中溶解能力分为难溶于油相、能溶于油相两类。
其中,所述难溶于油相的药物包括但不限于β-乳球蛋白、阿必鲁肽、艾塞那肽、奥曲肽、贝拉鲁肽、达托霉素、度拉糖肽、杆菌肽、戈舍瑞林、谷胱甘肽、环孢菌素、角蛋白、可比司它、兰瑞肽、利拉鲁肽、亮丙瑞林、卵白蛋白、洛塞那肽、米卡净芬、那法瑞林、曲普瑞林、沙格斯汀、索玛鲁肽、万古霉素、胸腺五肽、依多曲肽、胰岛素中的一种或多种的组合;所述能溶于油相的药物包括但不限于奥氮平、阿戈美拉汀、阿拉普利、阿普洛尔、艾司西酞普兰、奥卡西平、保泰松、倍他洛尔、倍他米松、苯妥英钠、比索洛尔、吡贝地尔、吡硫醇、吡罗昔康、苄氟噻嗪、表柔比星、醋丁洛尔、达格列净、地塞米松、多奈哌齐、多柔比星、多沙唑嗪、氟尿嘧啶、高三尖杉酯碱、格列波脲、格列齐特、胍乙啶、环丙贝特、环磷酰胺、磺吡酮、加兰他敏、甲氨蝶呤、甲泼尼龙、姜黄素、金刚烷胺、肼屈嗪、卡马西平、可的松、克伦特罗、喹硫平、喹那普利、拉贝洛尔、雷沙吉兰、利多卡因、利培酮、硫必利、罗非昔布、罗替戈汀、氯氮平、美法仑、美沙酮、美托洛尔、米诺环素、纳多洛尔、纳洛酮、帕利哌酮、哌唑嗪、培哚普利、泼尼松、泼尼松龙、扑米酮、羟基喜树碱、氢化可的松、曲吡那敏、曲普瑞林、曲唑酮、去甲文拉法辛、群多普利、三氟哌啶醇、三尖杉酯碱、沙芬酰胺、沙格列汀、石杉碱甲、水杨酸镁、司来吉兰、他克林、泰必利、特布他林、特拉唑嗪、替尼泊苷、酮洛芬、维格列汀、乌拉地尔、西格列汀、西拉普利、西酞普兰、西替利嗪、盐酸二甲双胍、盐酸羟考酮、伊马替尼、依那普利、依托泊苷、乙氟利嗪、吲达帕胺、长春新碱、阿托伐他汀、甲唑胺中的一种或多种的组合。
进一步的,上述化学药物药学上可接受的盐形式包括但不限于盐酸盐、硫酸盐、醋酸盐、水杨酸盐、磺酸盐、枸橼酸盐等多种药学上可用的盐形式。
其中,所述亲油性聚合物包括但不限于疏水性壳聚糖及其衍生物、醋酸羟丙甲纤维素琥珀酸酯及其衍生物、聚甲基丙烯酸酯及其衍生物、聚醋酸乙烯邻苯二甲酸酯及其衍生物、聚醋酸乙烯邻苯二甲酸酯及其衍生物、聚乙基纤维素及其衍生物、缩醛化右旋糖酐及其衍生物、聚乳酸及其衍生物、聚乳酸-羟基乙酸共聚物及其衍生物、聚 (N-异丙基丙烯酰胺)及其类似物和衍生物、聚己内酯及其衍生物、聚烷基-氰基丙烯酸酯及其衍生物、聚苯乙烯及其衍生物、聚乳酸/聚乙二醇嵌段共聚物及其衍生物、聚乳酸羟基乙酸/聚乙二醇嵌段共聚物及其衍生物、聚乳酸羟基乙酸/聚赖氨酸嵌段共聚物及其衍生物、聚乳酸羟基乙酸/聚天冬氨酸嵌段共聚物及其衍生物、聚乳酸羟基乙酸/聚谷氨酸嵌段共聚物及其衍生物、聚乙二醇/聚赖氨酸嵌段共聚物及其衍生物、聚乙二醇/ 聚天冬氨酸嵌段共聚物及其衍生物、聚乙二醇/聚谷氨酸嵌段共聚物及其衍生物或聚甲基丙烯酸/聚甲基丙烯酸甲酯嵌段共聚物及其衍生物、脂肪酸及其衍生物、甘油酯及其衍生物、蜡质类材料及其衍生物、类固醇类材料及其衍生物和磷脂类材料及其衍生物中一种或多种的组合。
其中,所述乳化剂包括但不限于油酸皂、硬脂酸皂、月桂酸皂、松香油皂、烷基硫酸盐、烷基苯磺酸盐、烷基磺酸盐、烷基萘基磺酸盐、木质素磺酸盐、磷酸酯盐、硫酸酯盐、季铵盐、烷基铵盐、卵磷脂、脂肪酸甘油酯、聚乙烯醇、蔗糖脂肪酸酯、脂肪酸山梨坦、聚山梨酯、聚氧乙烯脂肪酸酯、聚氧乙烯脂肪醇醚、聚氧乙烯-聚氧丙烯嵌段共聚物、碳氟表面活性剂、含硅表面活性剂、生物表面活性剂、冠醚型表面活性剂、阿拉伯胶、西黄蓍胶、明胶、杏树胶、卵黄、聚乙烯吡咯烷酮或固体微粒乳化剂中一种或多种的组合。
其中,所述溶液I包括但不限于纯水、氯化钠溶液、硝酸钠溶液、硫酸钠溶液、氯化钾溶液、硝酸钾溶液、硫酸钾溶液、氯化钙溶液、硝酸钙溶液、硫酸钙溶液、氯化铵溶液、硝酸铵溶液、硫酸铵溶液、氯化镁溶液、硝酸镁溶液、硫酸镁溶液、氯化铝溶液、硝酸铝溶液、硫酸铝溶液、硫酸锌溶液、碳酸钠溶液、碳酸氢钠溶液、碳酸钾溶液中一种或多种的组合;所述的盐的含量范围为1%-75%(w/w)。
其中,所述溶剂I包括但不限于苯,正丁醇、四氯化碳、氯仿、环己烷、环戊烷、二氯甲烷、二氯乙烷、乙酸乙酯、乙酸甲酯、乙醚、正庚烷、正己烷、甲乙酮、异辛烷、戊烷、二丙醚、四氯乙烷、甲苯、三氯乙烷、二甲苯、碳酸二甲酯、甲醇、乙醇、乙二醇、二乙二醇、异丙醇、1,2-丙二醇、1,3-丙二醇、叔丁醇、1,2-丁二醇、1, 3-丁二醇、1,4-丁二醇、1,5-戊二醇、2-丁氧基乙醇、甲基二乙醇胺、丙酮、二乙醇胺、乙腈、乙胺、二乙烯三胺、二甲基亚砜、四氢呋喃、二甲基甲酰胺、二甲氧基乙烷、吡啶、乙酸、乙醛、二氧六环中一种或多种的组合。
作为优选,步骤(1)中,药物胶体微粒的分散方法:难溶于油相的药物使用自发溶剂扩散法;能溶于油相的药物使用机械球磨法。
作为优选,步骤(1)中,药物胶体微粒的粒径为50-400nm。
作为优选,步骤(2)中,形成O/W乳剂的乳化方法:膜乳化或连续流。
作为优选,步骤(2)中,油相中的药物含量:能溶于油相的药物含量为其在溶剂Ⅰ中的饱和溶解度的15倍以上。
作为优选,步骤(2)中,水相和油相的体积比为10-100。
本发明的发明作用原理(见图15所示):
一、使用与药物微粒表面电性相反的载体材料,通过载体材料与药物微粒间的静电相互作用,将载体材料吸附在微粒表面,从而对微粒表面进行修饰。通过将亲水或者半亲水的药物微粒表面转化为亲油的载体材料吸附层,进而使得药物微粒能稳定分散于油相并干预药物微粒在油水两相间的分配,实现对药物的高效包载(图1)。例如本发明实施例2中使用带正电荷的精胺修饰的缩醛化右旋糖酐(载体材料)对带负电荷的胰岛素微粒(药物微粒)进行微粒表面的亲油性伪装,并采用本发明的快速固化策略,最终制得胰岛素微球的包封率为96.69%,载药量可达48.34%。而胰岛素通过传统的复乳法制得的聚乳酸羟基乙微球,其包封率为80.84%,载药量仅为2.50%[1]。
二、当药物在油相中有一定溶解度时,加入表面电性相反的载体材料亦可以通过亲油性伪装干预药物微粒在油水两相间的分配。但由于这类药物本身在油相中有一定溶解度,故仍有部分药物以游离形式存在于油相并持续向水相扩散。对此本发明给出的策略是通过提高油相中的总药物量和快速移除乳滴中有机溶剂的固化方法,降低乳滴固化时间内由油相向水相扩散的药物占总药物量的百分比。由于在有限的固化时间内药物从油相向水相中的扩散量是一定的,因此本方法通过减少微球固化时间和降低扩散药量的占比,可以实现微球对于此类药物的高效包载。例如本发明实施例4中聚乳酸-羟基乙酸共聚物和精胺修饰的缩醛化右旋糖酐包裹的甲基泼尼龙微球的载药量为 67.61%、包封率为84.52%。而使用传统乳化法制得的聚乳酸羟基乙微球,其包封率为 15.60,载药量为12.48%。从另一个角度讲,本发明提供的策略可以拓宽传统乳化法制备微球在不同种类药物上的应用范围。
本发明主要通过两方面来提高微球的载药量:
1、在步骤(1)中将药物由分子转变为胶体微粒,本发明人通过研究发现,使用含药物胶体微粒的油相后,能够提高微球载药量的原因在于:对于药物活性分子的亲油性伪装,能有效改变其分配特性,大幅减少参与油水两相间分配的药物量,从而降低药物的泄露速率。
2、在步骤(3)中使用快速固化的手段将乳化生成的乳滴制备成微球,大幅减少药物参与油水两相间分配的时间,从而在药物的泄露速率一定的情况下,减少药物泄露的总量,提高微球的载药量。
有益效果:
本发明方法能够有效提高微球的载药量,可将载药微球的包封率控制在80%以上,降低了聚合物的用量,减少生产成本,提高治疗效率,进而减少给药频次、提高患者的用药依从性。并且大幅扩展了O/W乳化法制备微球的应用范围,极大地推动了微球制剂的临床转化。
附图说明
图1为实施例1条件下制备的含AcDX-SP的INS胶体微粒的粒径分布;
图2为实施例1条件下制备的精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的 INS微球(INS@AcDX-SP)的光学显微镜照片;
图3为实施例2条件下制备的含AcDX-SP的INS胶体微粒的粒径分布;
图4为实施例2条件下制备的精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的 INS微球(INS@AcDX-SP)的光学显微镜照片;
图5为实施例3条件下制备的含AcDX-SP的β-LG胶体微粒的粒径分布;
图6为实施例3条件下制备的精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的β- LG微球(β-LG@AcDX-SP)的光学显微镜照片;
图7为实施例4条件下制备的含AcDX-SP的EXT胶体微粒的粒径分布;
图8为实施例4条件下制备的精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的 EXT微球(EXT@AcDX-SP)的光学显微镜照片;
图9为实施例4条件下制备的含PLGA和AcDX-SP的MP胶体微粒的粒径分布;
图10为实施例4条件下制备的聚乳酸-羟基乙酸共聚物(PLGA)和精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的MP微球(MP@PLGA&AcDX-SP)的光学显微镜照片;
图11为实施例5条件下制备的含AcDX-SP的BMZ胶体微粒的粒径分布;
图12为实施例5条件下制备的精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的 BMZ微球(BMZ@AcDX-SP)的光学显微镜照片;
图13为实施例5条件下制备的含AcDX-SP的DNP胶体微粒的粒径分布;
图14为实施例5条件下制备的精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的 DNP微球(DNP@AcDX-SP)的光学显微镜照片;
图15载体材料与药物微粒的吸附原理
具体实施方式
下面结合实施例对本发明作进一步的描述。
实施例1
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的胰岛素(INS)微球(INS@AcDX-SP)的制备。
取INS 10mg溶于0.012M HCl,配制0.5ml浓度为20mg/mL的INS溶液。在搅拌条件下,向其中加入4.5mL丙酮,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝, 3000rpm离心5min,弃上清,加入1mL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含AcDX-SP的INS胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂。乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为48.64%、包封率为 97.28%;平均粒径为70μm(图2)。
实施例2
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的胰岛素(INS)微球(INS@AcDX-SP)的制备。
取INS 20mg溶于0.012M HCl,配制1mL浓度为20mg/mL的INS溶液。在搅拌条件下,向其中依次加入6mL丙酮,1mL浓度为20mg/mL AcDX-SP的乙酸乙酯溶液,2mL乙酸乙酯,得到含AcDX-SP的INS胶体微粒作为油相。配制含60%MgCl2w/w的1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满30%MgCl2 w/w的水溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为47.48%、包封率为94.95%;平均粒径为50μm(图4)。
实施例3
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的β-乳球蛋白(β-LG)微球(β-LG@AcDX-SP)的制备。
取适量β-LG溶于水,配制浓度为50mg/mLβ-LG的水溶液,取50μL上述溶液,加入1mL四氢呋喃,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝,3000rpm离心5 min,弃上清,加入250μL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含AcDX-SP的β-LG胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满 1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为48.34%、包封率为96.69%;平均粒径为70μm(图6)。
实施例4
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的艾塞那肽(EXT)微球(EXT@AcDX-SP)的制备。
取适量EXT溶于水,配制浓度为50mg/mL EXT的水溶液,取50μL上述溶液,加入1mL乙腈,继续加入3倍体积的碳酸二甲酯使胶体微粒絮凝,3000rpm离心5 min,弃上清,加入250μL浓度为10mg/mL AcDX-SP的碳酸二甲酯溶液,探头超声,得到含AcDX-SP的EXT胶体微粒作为油相。配制2%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为41.67%、包封率为83.34%;平均粒径为65μm(图8)。
实施例5
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的牛血清白蛋白(BSA)微球(BSA@AcDX-SP)的制备。
取适量BSA溶于水,配制浓度为20mg/mL BSA的水溶液,取20μL上述溶液,加入1mL乙腈,继续加入3倍体积的碳酸二甲酯使胶体微粒絮凝,3000rpm离心5 min,弃上清,加入100μL浓度为10mg/mL AcDX-SP的碳酸二甲酯溶液,探头超声,得到含AcDX-SP的BSA胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为43.81%、包封率为87.61%;
实施例6
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的比伐卢定(BIV)微球(BIV@AcDX-SP)的制备。
取适量BIV溶于水,配制浓度为50mg/mL BIV的水溶液,取50μL上述溶液,加入1mL乙腈,继续加入3倍体积的碳酸二甲酯使胶体微粒絮凝,3000rpm离心5min,弃上清,加入250μL浓度为10mg/mL AcDX-SP的碳酸二甲酯溶液,探头超声,得到含AcDX-SP的BIV胶体微粒作为油相。配制2%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为44.77%、包封率为89.54%。
实施例7
本实施例公开了一种高包封率载蛋白药物微球,醋酸羟丙甲纤维素琥珀酸酯(HPMCAS)包裹的恩夫韦肽(ENF)微球(ENF@HPMCAS)的制备。
取适量ENF溶于水,配制浓度为20mg/mL ENF的水溶液,取20μL上述溶液,加入1mL乙腈,继续加入3倍体积的碳酸二甲酯使胶体微粒絮凝,3000rpm离心5 min,弃上清,加入100μL浓度为10mg/mL HPMCAS的二氯甲烷溶液,探头超声,得到含AcDX-SP的ENF胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为40.36%、包封率为80.73%。
实施例8
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的谷胱甘肽(GSH)微球(GSH@AcDX-SP)的制备。
取GSH20 mg溶于水,配制1mL浓度为20mg/mL的GSH溶液。在搅拌条件下,向其中依次加入6mL乙腈,1mL的浓度为20mg/mL AcDX-SP的乙酸乙酯溶液,2 mL乙酸乙酯,得到含AcDX-SP的GSH胶体微粒作为油相。配制含40%MgCO3 w/w 的1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成 O/W型乳剂,乳剂中的有机溶剂在充满20%MgCO3w/w的水溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为43.06%、包封率为86.12%;
实施例9
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的那法瑞林(NFL)微球(NFL@AcDX-SP)的制备。
取NFL20 mg溶于水,配制1mL浓度为20mg/mL的NFL溶液。在搅拌条件下,向其中依次加入6mL丙酮,1mL浓度为20mg/mL AcDX-SP的乙酸乙酯溶液,2mL 乙酸乙酯,得到含AcDX-SP的NFL胶体微粒作为油相。配制含60%MgCl2 w/w的 1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W 型乳剂,乳剂中的有机溶剂在充满30%MgCl2w/w的水溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为45.83%、包封率为91.65%;
实施例10
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的奥曲肽(OCT)微球(OCT@AcDX-SP)的制备。
取适量OCT溶于水,配制浓度为20mg/mL OCT的水溶液,取20μL上述溶液,加入1mL丙酮,继续加入3倍体积的碳酸二甲酯使胶体微粒絮凝,3000rpm离心5 min,弃上清,加入40μL浓度为10mg/mL AcDX-SP的碳酸二甲酯溶液,探头超声,得到含AcDX-SP的OCT胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满 1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为44.84%、包封率为89.67%;
实施例11
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的亮丙瑞林(LEU)微球(LEU@AcDX-SP)的制备。
取适量LEU溶于20%乙腈的水溶液,配制浓度为50mg/mL LEU的溶液,取20 μL上述溶液,加入1mL乙腈,继续加入3倍体积的碳酸二甲酯使胶体微粒絮凝, 3000rpm离心5min,弃上清,加入100μL浓度为10mg/mL AcDX-SP的碳酸二甲酯溶液,探头超声,得到含AcDX-SP的LEU胶体微粒作为油相。配制1%聚乙烯醇 (PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为43.29%、包封率为86.57%;
实施例12
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的洛塞那肽(LOX)微球(LOX@AcDX-SP)的制备。
取适量LOX溶于水,配制浓度为50mg/mL LOX的水溶液,取20μL上述溶液,加入1mL丙酮,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝,3000rpm离心5min,弃上清,加入100μL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含 AcDX-SP的LOX胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为46.91%、包封率为93.82%;
实施例13
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的兰瑞肽(LAN)微球(LAN@AcDX-SP)的制备。
取适量LAN溶于水,配制浓度为20mg/mL LAN的水溶液,取20μL上述溶液,加入1mL甲醇,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝,3000rpm离心5min,弃上清,加入40μL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含 AcDX-SP的LAN胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为46.23%、包封率为92.46%;
实施例14
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的阿必鲁肽(ABI)微球(ABI@AcDX-SP)的制备。
取适量ABI溶于水,配制浓度为20mg/mL ABI的水溶液,取20μL上述溶液,加入1mL丙酮,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝,3000rpm离心5min,弃上清,加入40μL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含 AcDX-SP的ABI胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为43.81%、包封率为87.62%;
实施例15
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的曲普瑞林(TRP)微球(TRP@AcDX-SP)的制备。
取适量TRP溶于水,配制浓度为50mg/mL TRP的水溶液,取20μL上述溶液,加入1mL丙酮,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝,3000rpm离心5min,弃上清,加入100μL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含 AcDX-SP的TRP胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为46.59%、包封率为93.18%;
实施例16
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的贝拉鲁肽(BER)微球(BER@AcDX-SP)的制备。
取适量BER溶于水,配制浓度为50mg/mL BER的水溶液,取20μL上述溶液,加入1mL丙酮,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝,3000rpm离心5min,弃上清,加入100μL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含 AcDX-SP的BER胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为43.71%、包封率为87.41%;
实施例17
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的度拉糖肽(DUL)微球(DUL@AcDX-SP)的制备。
取适量DUL溶于水,配制浓度为50mg/mL DUL的水溶液,取20μL上述溶液,加入1mL丙酮,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝,3000rpm离心5min,弃上清,加入100μL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含AcDX-SP的DUL胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为43.27%、包封率为86.53%;
实施例18
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的利拉鲁肽(LIR)微球(LIR@AcDX-SP)的制备。
取适量LIR溶于水,配制浓度为30mg/mL LIR的水溶液,取20μL上述溶液,加入1mL丙酮,继续加入3倍体积的乙酸乙酯使胶体微粒絮凝,3000rpm离心5min,弃上清,加入60μL浓度为10mg/mL AcDX-SP的乙酸乙酯溶液,探头超声,得到含 AcDX-SP的LIR胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为42.34%、包封率为84.67%;
实施例19
本实施例公开了一种高包封率载蛋白药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的索玛鲁肽(SOM)微球(SOM@AcDX-SP)的制备。
取适量SOM溶于水,配制浓度为20mg/mL SOM的水溶液,取20μL上述溶液,加入1mL丙酮,继续加入3倍体积的碳酸二甲酯使胶体微粒絮凝,3000rpm离心5 min,弃上清,加入40μL浓度为10mg/mL AcDX-SP的碳酸二甲酯溶液,探头超声,得到含AcDX-SP的SOM胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满 1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为40.31%、包封率为80.62%;
实施例20
本实施例公开了一种高包封率载小分子药物微球,聚乳酸-羟基乙酸共聚物(PLGA)和精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的甲基泼尼龙(MP)微球 (MP@PLGA&AcDX-SP)的制备。
取MP 240mg、PLGA 36mg、AcDX-SP 144mg、研磨珠和6mL乙酸乙酯加至研磨罐,1200rpm研磨1h后,得到含PLGA和AcDX-SP的MP胶体微粒作为油相。配制1%聚乙烯醇(PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成 O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为67.61%、包封率为84.52%;平均粒径为50μm(图10)。
实施例21
本实施例公开了一种高包封率载小分子药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的倍他米松(BMZ)微球(BMZ@AcDX-SP)的制备。
取BMZ 180mg、AcDX-SP 120mg、研磨珠和6mL乙酸乙酯加至研磨罐,1200 rpm研磨1h后,得到含AcDX-SP的BMZ胶体微粒作为油相。配制1%聚乙烯醇 (PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为54.77%、包封率为91.28%;平均粒径为50μm(图12)。
实施例22
本实施例公开了一种高包封率载小分子药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的多奈哌齐(DNP)微球(DNP@AcDX-SP)的制备。
取DNP 180mg、AcDX-SP 120mg、研磨珠和6mL碳酸二甲酯加至研磨罐,1200 rpm研磨1h后,得到含AcDX-SP的DNP胶体微粒作为油相。配制1%聚乙烯醇 (PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为44.22%、包封率为73.70%;平均粒径为50μm(图14)。
实施例23
本实施例公开了一种高包封率载小分子药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的甲氨蝶呤(MTX)微球(MTX@AcDX-SP)的制备。
取MTX 180mg、AcDX-SP 120mg、研磨珠和6mL碳酸二甲酯加至研磨罐,1200 rpm研磨1h后,得到含AcDX-SP的MTX胶体微粒作为油相。配制1%聚乙烯醇 (PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为42.65%、包封率为71.08%。
实施例24
本实施例公开了一种高包封率载小分子药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的阿托伐他汀(ATV)微球(ATV@AcDX-SP)的制备。
取ATV 180mg、AcDX-SP 120mg、研磨珠和6mL碳酸二甲酯加至研磨罐,1200 rpm研磨1h后,得到含AcDX-SP的ATV胶体微粒作为油相。配制1%聚乙烯醇 (PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为47.63%、包封率为79.38%。
实施例25
本实施例公开了一种高包封率载小分子药物微球,精胺修饰的缩醛化右旋糖酐(AcDX-SP)包裹的甲唑胺(MTA)微球(MTA@AcDX-SP)的制备。
取MTA 180mg、AcDX-SP 120mg、研磨珠和6mL碳酸二甲酯加至研磨罐,1200 rpm研磨1h后,得到含AcDX-SP的MTA胶体微粒作为油相。配制1%聚乙烯醇 (PVA)溶液作为水相。将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1%聚乙烯醇(PVA)溶液的管路中被迅速移除,乳滴固化成微球。使用量筒接收微球,超纯水洗涤、干燥后,即得。制得的微球载药量为45.19%、包封率为75.32%。
实施例26~35
具体原料选择见表1,其它实验方法及参数同实施例2。
表1
实施例36~104
具体原料选择见表2,其它实验方法及参数同实施例4。
表2
/>
对比例1传统复乳法制备微球的方法
如通过传统乳化法制备药物的聚乳酸-羟基乙酸共聚物微球,聚乳酸-羟基乙酸共聚物溶于二氯甲烷。之后将药物水溶液和聚乳酸-羟基乙酸共聚物二氯甲烷溶液混合,超声形成初乳。将初乳加入到PVA溶液中,搅拌形成复乳。复乳搅拌,过滤,冻干,即得。
注:对比例与本发明区别在于,未将药物以胶体颗粒分散于油相,没有快速固化,其他条件一样。
按对比例1所述的传统方法制备的具体微球的包封率和载药量结果见表3。
表3
对比例2传统单乳法制备微球的方法
如通过传统乳化法制备药物的聚乳酸-羟基乙酸共聚物微球,药物和聚乳酸-羟基乙酸共聚物溶于二氯甲烷。之后将PVA溶液和聚乳酸-羟基乙酸共聚物二氯甲烷溶液混合,搅拌形成水包油乳剂。向乳剂中加入大量超纯水搅拌,过滤,冻干,即得。
注:对比例与本发明区别在于,未将药物以胶体颗粒分散于油相,没有快速固化,其他条件一样。
按对比例2所述的传统方法制备的具体微球的包封率和载药量结果见表4。
表4
参考文献:
[1]Ansary R H,Rahman M M,Awang M B,et al.Preparation,characterization,and in vitro release studies of insulin-loaded double-walledpoly(lactide-co-glycolide)microspheres[J].Drug Delivery and TranslationalResearch,2016,6(3):308-318.
Claims (1)
1.一种提高微球载药量的方法,其特征在于由以下步骤任意一种实现:
取甲基泼尼龙 240 mg、聚乳酸-羟基乙酸共聚物36 mg、精胺修饰的缩醛化右旋糖酐144 mg、研磨珠和6 mL乙酸乙酯加至研磨罐,1200 rpm 研磨1 h后,得到含PLGA和精胺修饰的缩醛化右旋糖酐的甲基泼尼龙胶体微粒作为油相;配制1%聚乙烯醇溶液作为水相;将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1 %聚乙烯醇溶液的管路中被迅速移除,乳滴固化成微球;使用量筒接收微球,超纯水洗涤、干燥后,即得;
取倍他米松 180 mg、精胺修饰的缩醛化右旋糖酐 120 mg、研磨珠和6 mL乙酸乙酯加至研磨罐,1200 rpm 研磨1 h后,得到含精胺修饰的缩醛化右旋糖酐的倍他米松 胶体微粒作为油相;配制1%聚乙烯醇溶液作为水相;将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1 %聚乙烯醇溶液的管路中被迅速移除,乳滴固化成微球;使用量筒接收微球,超纯水洗涤、干燥后,即得;
取多奈哌齐 180 mg、精胺修饰的缩醛化右旋糖酐 120 mg、研磨珠和6 mL碳酸二甲酯加至研磨罐,1200 rpm 研磨1 h后,得到含精胺修饰的缩醛化右旋糖酐的多奈哌齐 胶体微粒作为油相;配制1%聚乙烯醇溶液作为水相;将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1 %聚乙烯醇溶液的管路中被迅速移除,乳滴固化成微球;使用量筒接收微球,超纯水洗涤、干燥后,即得;
取甲氨蝶呤 180 mg、精胺修饰的缩醛化右旋糖酐 120 mg、研磨珠和6 mL碳酸二甲酯加至研磨罐,1200 rpm 研磨1 h后,得到含精胺修饰的缩醛化右旋糖酐的甲氨蝶呤 胶体微粒作为油相;配制1%聚乙烯醇溶液作为水相;将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1 %聚乙烯醇溶液的管路中被迅速移除,乳滴固化成微球;使用量筒接收微球,超纯水洗涤、干燥后,即得;
取阿托伐他汀 180 mg、精胺修饰的缩醛化右旋糖酐 120 mg、研磨珠和6 mL碳酸二甲酯加至研磨罐,1200 rpm 研磨1 h后,得到含精胺修饰的缩醛化右旋糖酐的阿托伐他汀 胶体微粒作为油相;配制1%聚乙烯醇溶液作为水相;将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1 %聚乙烯醇溶液的管路中被迅速移除,乳滴固化成微球;使用量筒接收微球,超纯水洗涤、干燥后,即得;
取甲唑胺 180 mg、精胺修饰的缩醛化右旋糖酐 120 mg、研磨珠和6 mL碳酸二甲酯加至研磨罐,1200 rpm 研磨1 h后,得到含精胺修饰的缩醛化右旋糖酐的甲唑胺 胶体微粒作为油相;配制1%聚乙烯醇溶液作为水相;将两相用注射泵通入连续流装置乳化形成O/W型乳剂,乳剂中的有机溶剂在充满1 %聚乙烯醇溶液的管路中被迅速移除,乳滴固化成微球;使用量筒接收微球,超纯水洗涤、干燥后,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111311957.4A CN114081867B (zh) | 2021-11-08 | 2021-11-08 | 一种提高微球载药量的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111311957.4A CN114081867B (zh) | 2021-11-08 | 2021-11-08 | 一种提高微球载药量的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114081867A CN114081867A (zh) | 2022-02-25 |
CN114081867B true CN114081867B (zh) | 2023-12-19 |
Family
ID=80299180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111311957.4A Active CN114081867B (zh) | 2021-11-08 | 2021-11-08 | 一种提高微球载药量的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114081867B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115252799A (zh) * | 2022-07-27 | 2022-11-01 | 中国药科大学 | 一种基于相转移抑制原理制备的超高载药复合物及其方法 |
CN116004019B (zh) * | 2023-01-05 | 2024-03-15 | 广西博生生物科技有限公司 | 一种明胶与γ蛋白膜乳化形成的明胶载体结构均聚物的制备与应用 |
CN116173188B (zh) * | 2023-02-07 | 2023-12-01 | 浙江大学 | 口服glp-1类似物固体脂质纳米粒及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102209531A (zh) * | 2008-11-14 | 2011-10-05 | 梨花女子大学校产学协力团 | 高分子微球的制造方法和通过该方法制造的高分子微球 |
CN107308118A (zh) * | 2017-07-07 | 2017-11-03 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺plga微球及其制备方法 |
CN112603892A (zh) * | 2020-12-18 | 2021-04-06 | 中国药科大学 | 一种载药微球及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102047983B1 (ko) * | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
-
2021
- 2021-11-08 CN CN202111311957.4A patent/CN114081867B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102209531A (zh) * | 2008-11-14 | 2011-10-05 | 梨花女子大学校产学协力团 | 高分子微球的制造方法和通过该方法制造的高分子微球 |
CN107308118A (zh) * | 2017-07-07 | 2017-11-03 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺plga微球及其制备方法 |
CN112603892A (zh) * | 2020-12-18 | 2021-04-06 | 中国药科大学 | 一种载药微球及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Komal ShaHani 等.Pharmaceutics,Preformulation and Drug Delivery highly Loaded,Sustained-Release Microparticles of Curcumin for Chemoprevention.《Journal of Pharmaceutical Sciences》.2011,第100卷(第7期),第2599-2609页. * |
Pharmaceutics,Preformulation and Drug Delivery highly Loaded,Sustained-Release Microparticles of Curcumin for Chemoprevention;Komal ShaHani 等;《Journal of Pharmaceutical Sciences》;20110114;第100卷(第7期);第2599-2609页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114081867A (zh) | 2022-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114081867B (zh) | 一种提高微球载药量的方法 | |
US5288502A (en) | Preparation and uses of multi-phase microspheres | |
US20230126007A1 (en) | Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents | |
Naik et al. | Development of sustained release micro/nanoparticles using different solvent emulsification technique: A review | |
Mora-Huertas et al. | Polymer-based nanocapsules for drug delivery | |
Reis et al. | Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles | |
Yeo et al. | Control of encapsulation efficiency and initial burst in polymeric microparticle systems | |
Couvreur et al. | Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides | |
US6395302B1 (en) | Method for the preparation of microspheres which contain colloidal systems | |
Chaisri et al. | Preparation and characterization of cephalexin loaded PLGA microspheres | |
KR101741982B1 (ko) | 이중 약물 전달을 위한 다공성 생분해성 고분자 미립자 및 그의 제조 방법 | |
AU2014283692B2 (en) | Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile | |
Padalkar et al. | Microparticles: an approach for betterment of drug delivery system | |
Bolzinger et al. | Improvement of a bovine serum albumin microencapsulation process by screening design | |
Barba et al. | Biocompatible nano-micro-particles by solvent evaporation from multiple emulsions technique | |
KR101006667B1 (ko) | 약물을 함유하는 생분해성 미립자의 제조방법 | |
KR101831417B1 (ko) | 자발적 공극 폐쇄 기능성을 갖는 고분자 미립구 및 이의 제조방법 | |
Zhang et al. | An improvement of double emulsion technique for preparing bovine serum albumin-loaded PLGA microspheres | |
Erden et al. | Factors influencing release of salbutamol sulphate from poly (lactide-co-glycolide) microspheres prepared by water-in-oil-in-water emulsion technique | |
US20110236496A1 (en) | Emulsions for Microencapsulation Comprising Biodegradable Surface-Active Block Copolymers as Stabilizers | |
Sohier et al. | Release of small water-soluble drugs from multiblock copolymer microspheres: a feasibility study | |
Nguyen et al. | Emulsion techniques for producing polymer based drug delivery systems | |
Yang et al. | Thymosin-loaded enteric microspheres for oral administration: Preparation and in vitro release studies | |
Ruan et al. | Effects of polymer, organic solvent and mixing strength on integrity of proteins and liposomes encapsulated in polymeric microspheres fabricated by the double emulsion process | |
Adebileje et al. | Modelling particle size, drug loading and release of BSA encapsulated into PLGA nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |